Practical aspects of targeting IL-6 in COVID-19 disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32409439.
- Also identified by DOI 10.3949/ccjm.87a.ccc018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety.